Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Coronary drug-eluting stents: from design optimization to newer strategies.

Sun D, Zheng Y, Yin T, Tang C, Yu Q, Wang G.

J Biomed Mater Res A. 2014 May;102(5):1625-40. doi: 10.1002/jbm.a.34806. Epub 2013 Jul 1. Review.

PMID:
23703913
2.

Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.

Waksman R, Pakala R.

EuroIntervention. 2009 Dec 15;5 Suppl F:F36-42. doi: 10.4244/EIJV5IFA6. Review.

PMID:
22100674
3.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
4.

Design criteria for the ideal drug-eluting stent.

Ako J, Bonneau HN, Honda Y, Fitzgerald PJ.

Am J Cardiol. 2007 Oct 22;100(8B):3M-9M. Review.

PMID:
17950830
5.

Long-term patient benefit with biodegradable polymer biolimus eluting stent.

Corti R.

Minerva Cardioangiol. 2012 Dec;60(6):629-36. Review.

PMID:
23147439
6.

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F.

BMJ. 2013 Nov 8;347:f6625. doi: 10.1136/bmj.f6625.

7.
8.

Drug-eluting stents.

García-García HM, Vaina S, Tsuchida K, Serruys PW.

Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Review.

PMID:
17091802
9.

Drug-eluting stents for coronary artery disease: a review.

Martin DM, Boyle FJ.

Med Eng Phys. 2011 Mar;33(2):148-63. doi: 10.1016/j.medengphy.2010.10.009. Review.

PMID:
21075668
10.

Vascular remodeling after coronary stent implantation.

Vorpahl M, Virmani R, Ladich E, Finn AV.

Minerva Cardioangiol. 2009 Oct;57(5):621-8. Review.

PMID:
19838152
11.

The future of drug-eluting stents.

Kukreja N, Onuma Y, Daemen J, Serruys PW.

Pharmacol Res. 2008 Mar;57(3):171-80. doi: 10.1016/j.phrs.2008.01.012. Epub 2008 Feb 2. Review.

PMID:
18339557
12.

Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.

Chen SL, Ye F, Zhang JJ, Zou JJ, Qian XS, Li F, Yang S, Ge Z, Shan SJ, Li XB, Xu T, Kan J, Lin L, Han YL.

Cardiovasc Ther. 2013 Aug;31(4):193-200. doi: 10.1111/j.1755-5922.2012.00319.x.

PMID:
22954234
13.

Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries.

Bonello L, De Labriolle A, Lemesle G, Roy P, Steinberg DH, Slottow TL, Xue Z, Torguson R, Kaneshige K, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R.

Am J Cardiol. 2009 Feb 15;103(4):496-500. doi: 10.1016/j.amjcard.2008.10.028.

PMID:
19195509
14.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384
15.

Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, Kaiser C, D'Ascenzo F, Frati G, Mancone M, Genereux P, Stone GW.

J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. Review.

16.

A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati A.

Eur Heart J. 2009 Apr;30(8):923-31. doi: 10.1093/eurheartj/ehp044. Epub 2009 Feb 24.

PMID:
19240066
17.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

18.

Impact of stent strut design in metallic stents and biodegradable scaffolds.

Foin N, Lee RD, Torii R, Guitierrez-Chico JL, Mattesini A, Nijjer S, Sen S, Petraco R, Davies JE, Di Mario C, Joner M, Virmani R, Wong P.

Int J Cardiol. 2014 Dec 20;177(3):800-8. doi: 10.1016/j.ijcard.2014.09.143. Epub 2014 Oct 7. Review.

PMID:
25449502
19.

The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.

Huang Y, Venkatraman SS, Boey FY, Umashankar PR, Mohanty M, Arumugam S.

J Interv Cardiol. 2009 Oct;22(5):466-78. doi: 10.1111/j.1540-8183.2009.00489.x. Epub 2009 Jul 13.

PMID:
19627432
20.

Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.

Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, Fusaro M, Schneider S, Schulz S, Ibrahim T, Ott I, Massberg S, Laugwitz KL, Kastrati A.

JACC Cardiovasc Interv. 2013 Dec;6(12):1267-74. doi: 10.1016/j.jcin.2013.06.015.

Supplemental Content

Support Center